2-[2-Methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetic acid | 78657-36-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[2-Methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetic acid
• 英文别名: 2-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetic acid
• CAS: 78657-36-0
• 化学式: C₁₇H₂₆N₄O₇S
• 分子量: 430.482
• InChiKey: KJJMVFQQCOFVCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  178
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-[2-Methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetic acid 在 N-甲基吗啉 、 二氯磷酸苯酯 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

  摘要：

  The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.06.014
• 作为产物：
  描述：

  2-(5-((tert-butoxycarbonyl)amino)-1,2,4-thiadiazol-3-yl)-2-oxoacetic acid 、 tert-butyl 2-(aminooxy)-2-methylpropanoate 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-[2-Methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetic acid
  参考文献：
  名称：

  Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

  摘要：

  The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.06.014

文献信息

• MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  申请人：AULAKH Virender Singh

  公开号：US20150266867A1

  公开（公告）日：2015-09-24

  This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

  这项发明通常涉及公式I的抗菌化合物，如本文进一步描述，并其药用盐和制剂。在某些方面，该发明涉及使用这些化合物治疗由革兰氏阴性细菌引起的感染的方法。
• CEPHEM COMPOUND HAVING PYRIDINIUM GROUP
  申请人：Nishitani Yasuhiro

  公开号：US20140114060A1

  公开（公告）日：2014-04-24

  The present invention provides a novel compound which has a broad antibacterial spectrum and particularly exhibits a high antibacterial activity on β-lactamase-producing gram-negative bacteria. Specifically provided are: a compound represented by formula (I) wherein the meaning of each symbol is as defined in the description, an amino-group-protected form of a type of the compound which has the amino group on a ring in a position-7 side chain, or a pharmaceutically acceptable salt of the compound or the amino-group-protected form; and a pharmaceutical composition containing the compound, the amino-group-protected form or the pharmaceutically acceptable salt.

  本发明提供了一种新型化合物，具有广泛的抗菌谱，特别对产β-内酰胺酶的革兰氏阴性细菌表现出高抗菌活性。具体提供的是：一种由式(I)表示的化合物，其中每个符号的含义如描述中定义的那样，一种在环上具有氨基团的化合物的保护形式，该化合物在位置-7侧链上具有氨基团，或者化合物或氨基团保护形式的药用可接受盐；以及含有该化合物、氨基团保护形式或药用可接受盐的药物组合物。
• [EN] REACTIONS OF THIADIAZOLYL-OXIMINOACETIC ACID DERIVATIVE COMPOUNDS<br/>[FR] RÉACTIONS DE COMPOSÉS DÉRIVÉS DE L'ACIDE THIADIAZOLYL-OXIMINOACÉTIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015196077A1

  公开（公告）日：2015-12-23

  This disclosure relates to an improved synthesis of cephalosporin antibiotic compounds such as ceftolozane, and compositions and methods of use thereof. Thiadiazolyl-oximinoacetic acid compounds such as TATD can be reacted to yield the activated thiadiazolyl-oximinoacetic acid methanesulfonate ester compounds useful in the manufacture of cephalosporin antibiotic compounds.

  本公开涉及改进的头孢菌素类抗生素化合物（例如头孢洛珊），以及其组成和使用方法的合成。可以将噻二唑基氧肟乙酸化合物（如TATD）反应以产生活化的噻二唑基氧肟乙酸甲磺酸酯化合物，这些化合物可用于制造头孢菌素类抗生素化合物。
• Cephem compounds
  申请人：——

  公开号：US20040248875A1

  公开（公告）日：2004-12-09

  The present invention relates to a compound of the formula [I]: wherein A is lower alkylene or lower alkenylene; R1 is lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl or protected amino(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene; R3 and R5 are independently amino or protected amino; and R4 is carboxy or protected carboxy, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier. 1

  本发明涉及一种化合物，其化学式为[I]：其中，A为较低的烷基或烯基烷基；R1为较低的烷基、羟基(较低)烷基、保护羟基(较低)烷基、氨基(较低)烷基或保护氨基(较低)烷基，R2为氢或氨基保护基，或R1和R2结合形成较低的烷基；R3和R5独立地为氨基或保护氨基；R4为羧基或保护羧基，或其药学上可接受的盐，以及制备化学式[I]的化合物的方法和包含化学式[I]的化合物与药学上可接受的载体混合的制药组合物。
• Monobactam organic compounds for the treatment of bacterial infections
  申请人：Novartis AG

  公开号：US10369138B2

  公开（公告）日：2019-08-06

  This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

  本发明一般涉及式 I 的抗菌化合物、 及其药学上可接受的盐类和制剂。在某些方面，本发明涉及使用此类化合物治疗感染（如革兰氏阴性细菌引起的感染）的方法。